2018 - Fellow, National Academy of Inventors
His primary areas of study are Stereochemistry, Biochemistry, Topoisomerase, Topoisomerase-I Inhibitor and Camptothecin. His Stereochemistry research incorporates elements of Enzyme inhibitor, Enzyme, Biological activity, Structure–activity relationship and Chemical synthesis. His Biochemistry research integrates issues from Cancer cell, Cell culture and Tubulin.
His work carried out in the field of Topoisomerase brings together such families of science as Lactam, Cleavage, Isoquinoline and Cytotoxicity. His Topoisomerase-I Inhibitor study integrates concerns from other disciplines, such as Combinatorial chemistry, Base pair, Molecular model and Hydrogen bond. His Camptothecin study combines topics from a wide range of disciplines, such as DNA damage and Point mutation.
Mark Cushman mainly investigates Stereochemistry, Biochemistry, Topoisomerase, Cytotoxicity and Topoisomerase-I Inhibitor. The Stereochemistry study combines topics in areas such as Lumazine synthase, Enzyme, Riboflavin synthase, Structure–activity relationship and Chemical synthesis. His work in Biochemistry addresses issues such as Cancer cell, which are connected to fields such as Cancer research.
His Topoisomerase research integrates issues from Camptothecin, Cleavage, Lactam and Isoquinoline. The study incorporates disciplines such as Cell culture and Biological activity in addition to Cytotoxicity. His research in Topoisomerase-I Inhibitor intersects with topics in Combinatorial chemistry and Molecular model.
His main research concerns Topoisomerase, Stereochemistry, Pharmacology, Biochemistry and Cancer research. Mark Cushman has included themes like Camptothecin, Cancer cell and Cytotoxicity in his Topoisomerase study. Mark Cushman combines subjects such as Lactam and Cell culture with his study of Cytotoxicity.
His work carried out in the field of Stereochemistry brings together such families of science as Telithromycin, Biological activity, Staphylococcus aureus, Ketolide and Structure–activity relationship. His DNA, DNA damage and Coenzyme A study in the realm of Biochemistry connects with subjects such as Methylenedioxy. The concepts of his Topoisomerase-I Inhibitor study are interwoven with issues in Side chain and Mechanism of action.
The scientist’s investigation covers issues in Topoisomerase, Cytotoxicity, Biochemistry, Topoisomerase-I Inhibitor and Stereochemistry. Topoisomerase connects with themes related to Pharmacology in his study. His Cytotoxicity research is multidisciplinary, relying on both Lactam, Cell culture, DNA, DNA damage and Cancer cell.
His Biochemistry research incorporates themes from Triazine and Antibacterial activity. His research integrates issues of Camptothecin, IC50, Cancer research and Structure–activity relationship in his study of Topoisomerase-I Inhibitor. His Stereochemistry study incorporates themes from Biological activity, Dna cleavage, Cleavage, Tyrosyl-DNA phosphodiesterase and Side chain.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex
Bart L. Staker;Michael D. Feese;Mark Cushman;Yves Pommier.
Journal of Medicinal Chemistry (2005)
Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
Mark Cushman;Dhanapalan Nagarathnam;D. Gopal;Asit K. Chakraborti.
Journal of Medicinal Chemistry (1991)
Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site.
Mark Cushman;Hu Ming He;John A. Katzenellenbogen;Chii M. Lin.
Journal of Medicinal Chemistry (1995)
Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents.
Mark Cushman;Dhanapalan Nagarathnam;D. Gopal;Hu Ming He.
Journal of Medicinal Chemistry (1992)
Synthesis and protein-tyrosine kinase inhibitory activities of flavonoid analogues.
Mark Cushman;Dhanapalan Nagarathnam;Debra L. Burg;Robert L. Geahlen.
Journal of Medicinal Chemistry (1991)
Selective Synthesis and Biological Evaluation of Sulfate-Conjugated Resveratrol Metabolites
Juma Hoshino;Eun Jung Park;Tamara P. Kondratyuk;Laura Marler.
Journal of Medicinal Chemistry (2010)
Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol.
Kshitij Thakkar;Robert L. Geahlen;Mark Cushman.
Journal of Medicinal Chemistry (1993)
Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison
Glenda Kohlhagen;Kenneth D. Paull;Mark Cushman;Pamela Nagafuji.
Molecular Pharmacology (1998)
Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.
Mark Cushman;Muthusamy Jayaraman;Jeffrey A. Vroman;Anna K. Fukunaga.
Journal of Medicinal Chemistry (2000)
A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex
Christophe Marchand;Smitha Antony;Kurt W. Kohn;Mark Cushman.
Molecular Cancer Therapeutics (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
National Institutes of Health
Technical University of Munich
Universität Hamburg
Western New England University
Rega Institute for Medical Research
Rega Institute for Medical Research
National Institutes of Health
National Institutes of Health
Max Planck Institute of Biochemistry
National Institutes of Health
Aalto University
University of Illinois at Chicago
Huazhong University of Science and Technology
University of Geneva
University of Washington
University of Otago
The Ohio State University
Heidelberg University
Hannover Medical School
University of Rhode Island
Texas A&M University
University of Giessen
University of Colorado Denver
University of Western Ontario
Newcastle University
University of Barcelona